Format

Send to

Choose Destination
Expert Rev Vaccines. 2015;14(11):1459-70. doi: 10.1586/14760584.2015.1081817.

Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.

Author information

1
a 1 Institute for Glycomics, Griffith University, Gold Coast, Australia.
2
b 2 Provincial Laboratory for Public Health, Alberta Health Services and Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.

Abstract

Group A streptococcal (Streptococcus pyogenes) diseases remain a major public health problem in developing countries as well as in the indigenous populations of developed countries. In view of the large number of Group A streptococcal infections and the potential for sequelae such as rheumatic heart disease, control strategies including the development of an anti-streptococcal vaccine that is able to prevent infection and colonization is important. In this article, we discuss the epidemiology and strain variability of Group A streptococcus and how this is rendering vaccine development more challenging. We discuss vaccine strategies with a focus on the conserved region of the M protein and present a viewpoint for the impediments and the way forward.

KEYWORDS:

CovR/S; GAS; J8-DT; J8-DT+rSpyCEP; M-protein-based vaccines; conserved region vaccine; group A streptococcus; pharyngitis; polyvalent vaccine; skin infection; vaccine

PMID:
26485214
DOI:
10.1586/14760584.2015.1081817
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center